Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2002 Feb;72(2):152–161. doi: 10.1136/jnnp.72.2.152

Protein aggregates and dementia: is there a common toxicity?

S Lovestone 1, D McLoughlin 1
PMCID: PMC1737746  PMID: 11796764

Abstract

This review considers some of the recent advances made in the understanding of the pathogenic proteins known to aggregate and be implicated in neurodegenerative dementing disorders. It concentrates on the two most obvious candidates for the role of toxic protein in Alzheimer's disease (AD)—ß-amyloid peptide and tau—but also considers other proteins in this disorder and in less common but equally devastating diseases.

Full Text

The Full Text of this article is available as a PDF (181.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abeliovich A., Schmitz Y., Fariñas I., Choi-Lundberg D., Ho W. H., Castillo P. E., Shinsky N., Verdugo J. M., Armanini M., Ryan A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000 Jan;25(1):239–252. doi: 10.1016/s0896-6273(00)80886-7. [DOI] [PubMed] [Google Scholar]
  2. Annaert W., De Strooper B. Presenilins: molecular switches between proteolysis and signal transduction. Trends Neurosci. 1999 Oct;22(10):439–443. doi: 10.1016/s0166-2236(99)01455-1. [DOI] [PubMed] [Google Scholar]
  3. Arrasate M., Pérez M., Armas-Portela R., Avila J. Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations. FEBS Lett. 1999 Mar 5;446(1):199–202. doi: 10.1016/s0014-5793(99)00210-0. [DOI] [PubMed] [Google Scholar]
  4. Baba M., Nakajo S., Tu P. H., Tomita T., Nakaya K., Lee V. M., Trojanowski J. Q., Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol. 1998 Apr;152(4):879–884. [PMC free article] [PubMed] [Google Scholar]
  5. Baker M., Litvan I., Houlden H., Adamson J., Dickson D., Perez-Tur J., Hardy J., Lynch T., Bigio E., Hutton M. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999 Apr;8(4):711–715. doi: 10.1093/hmg/8.4.711. [DOI] [PubMed] [Google Scholar]
  6. Bales K. R., Verina T., Dodel R. C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E. M., Little S. P., Cummins D. J. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997 Nov;17(3):263–264. doi: 10.1038/ng1197-263. [DOI] [PubMed] [Google Scholar]
  7. Beffert U., Danik M., Krzywkowski P., Ramassamy C., Berrada F., Poirier J. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Res Brain Res Rev. 1998 Jul;27(2):119–142. doi: 10.1016/s0165-0173(98)00008-3. [DOI] [PubMed] [Google Scholar]
  8. Bence N. F., Sampat R. M., Kopito R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 2001 May 25;292(5521):1552–1555. doi: 10.1126/science.292.5521.1552. [DOI] [PubMed] [Google Scholar]
  9. Bennett B. D., Babu-Khan S., Loeloff R., Louis J. C., Curran E., Citron M., Vassar R. Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem. 2000 Jul 7;275(27):20647–20651. doi: 10.1074/jbc.M002688200. [DOI] [PubMed] [Google Scholar]
  10. Bennett M. C., Bishop J. F., Leng Y., Chock P. B., Chase T. N., Mouradian M. M. Degradation of alpha-synuclein by proteasome. J Biol Chem. 1999 Nov 26;274(48):33855–33858. doi: 10.1074/jbc.274.48.33855. [DOI] [PubMed] [Google Scholar]
  11. Bertram L., Blacker D., Mullin K., Keeney D., Jones J., Basu S., Yhu S., McInnis M. G., Go R. C., Vekrellis K. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science. 2000 Dec 22;290(5500):2302–2303. doi: 10.1126/science.290.5500.2302. [DOI] [PubMed] [Google Scholar]
  12. Blacker D., Wilcox M. A., Laird N. M., Rodes L., Horvath S. M., Go R. C., Perry R., Watson B., Jr, Bassett S. S., McInnis M. G. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet. 1998 Aug;19(4):357–360. doi: 10.1038/1243. [DOI] [PubMed] [Google Scholar]
  13. Bondareff W., Harrington C. R., Wischik C. M., Hauser D. L., Roth M. Absence of abnormal hyperphosphorylation of tau in intracellular tangles in Alzheimer's disease. J Neuropathol Exp Neurol. 1995 Sep;54(5):657–663. doi: 10.1097/00005072-199509000-00007. [DOI] [PubMed] [Google Scholar]
  14. Borg J. P., Yang Y., De Taddéo-Borg M., Margolis B., Turner R. S. The X11alpha protein slows cellular amyloid precursor protein processing and reduces Abeta40 and Abeta42 secretion. J Biol Chem. 1998 Jun 12;273(24):14761–14766. doi: 10.1074/jbc.273.24.14761. [DOI] [PubMed] [Google Scholar]
  15. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–259. doi: 10.1007/BF00308809. [DOI] [PubMed] [Google Scholar]
  16. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995 May-Jun;16(3):271–284. doi: 10.1016/0197-4580(95)00021-6. [DOI] [PubMed] [Google Scholar]
  17. Brookes A. J., St Clair D. Synuclein proteins and Alzheimer's disease. Trends Neurosci. 1994 Oct;17(10):404–405. doi: 10.1016/0166-2236(94)90013-2. [DOI] [PubMed] [Google Scholar]
  18. Brown D. R. PrPSc-like prion protein peptide inhibits the function of cellular prion protein. Biochem J. 2000 Dec 1;352(Pt 2):511–518. [PMC free article] [PubMed] [Google Scholar]
  19. Brown D. R., Qin K., Herms J. W., Madlung A., Manson J., Strome R., Fraser P. E., Kruck T., von Bohlen A., Schulz-Schaeffer W. The cellular prion protein binds copper in vivo. Nature. 1997 Dec 18;390(6661):684–687. doi: 10.1038/37783. [DOI] [PubMed] [Google Scholar]
  20. Brown D. R., Schmidt B., Kretzschmar H. A. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature. 1996 Mar 28;380(6572):345–347. doi: 10.1038/380345a0. [DOI] [PubMed] [Google Scholar]
  21. Bruce M. E., Will R. G., Ironside J. W., McConnell I., Drummond D., Suttie A., McCardle L., Chree A., Hope J., Birkett C. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature. 1997 Oct 2;389(6650):498–501. doi: 10.1038/39057. [DOI] [PubMed] [Google Scholar]
  22. Buée L., Bussière T., Buée-Scherrer V., Delacourte A., Hof P. R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000 Aug;33(1):95–130. doi: 10.1016/s0165-0173(00)00019-9. [DOI] [PubMed] [Google Scholar]
  23. Buée L., Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol. 1999 Oct;9(4):681–693. doi: 10.1111/j.1750-3639.1999.tb00550.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Capell A., Steiner H., Romig H., Keck S., Baader M., Grim M. G., Baumeister R., Haass C. Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch. Nat Cell Biol. 2000 Apr;2(4):205–211. doi: 10.1038/35008626. [DOI] [PubMed] [Google Scholar]
  25. Conlon R. A., Reaume A. G., Rossant J. Notch1 is required for the coordinate segmentation of somites. Development. 1995 May;121(5):1533–1545. doi: 10.1242/dev.121.5.1533. [DOI] [PubMed] [Google Scholar]
  26. Conway K. A., Harper J. D., Lansbury P. T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998 Nov;4(11):1318–1320. doi: 10.1038/3311. [DOI] [PubMed] [Google Scholar]
  27. Cooper J. K., Schilling G., Peters M. F., Herring W. J., Sharp A. H., Kaminsky Z., Masone J., Khan F. A., Delanoy M., Borchelt D. R. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet. 1998 May;7(5):783–790. doi: 10.1093/hmg/7.5.783. [DOI] [PubMed] [Google Scholar]
  28. Cummings B. J., Cotman C. W. Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet. 1995 Dec 9;346(8989):1524–1528. doi: 10.1016/s0140-6736(95)92053-6. [DOI] [PubMed] [Google Scholar]
  29. Davies S. W., Turmaine M., Cozens B. A., DiFiglia M., Sharp A. H., Ross C. A., Scherzinger E., Wanker E. E., Mangiarini L., Bates G. P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997 Aug 8;90(3):537–548. doi: 10.1016/s0092-8674(00)80513-9. [DOI] [PubMed] [Google Scholar]
  30. Dayanandan R., Van Slegtenhorst M., Mack T. G., Ko L., Yen S. H., Leroy K., Brion J. P., Anderton B. H., Hutton M., Lovestone S. Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett. 1999 Mar 12;446(2-3):228–232. doi: 10.1016/s0014-5793(99)00222-7. [DOI] [PubMed] [Google Scholar]
  31. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998 Jan 22;391(6665):387–390. doi: 10.1038/34910. [DOI] [PubMed] [Google Scholar]
  32. DiFiglia M., Sapp E., Chase K. O., Davies S. W., Bates G. P., Vonsattel J. P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997 Sep 26;277(5334):1990–1993. doi: 10.1126/science.277.5334.1990. [DOI] [PubMed] [Google Scholar]
  33. Diamond M. I., Robinson M. R., Yamamoto K. R. Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):657–661. doi: 10.1073/pnas.97.2.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Dickson D. W., Lin W., Liu W. K., Yen S. H. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol. 1999 Oct;9(4):721–732. doi: 10.1111/j.1750-3639.1999.tb00553.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. El-Agnaf O. M., Jakes R., Curran M. D., Wallace A. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett. 1998 Nov 27;440(1-2):67–70. doi: 10.1016/s0014-5793(98)01419-7. [DOI] [PubMed] [Google Scholar]
  36. Ellerby L. M., Andrusiak R. L., Wellington C. L., Hackam A. S., Propp S. S., Wood J. D., Sharp A. H., Margolis R. L., Ross C. A., Salvesen G. S. Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem. 1999 Mar 26;274(13):8730–8736. doi: 10.1074/jbc.274.13.8730. [DOI] [PubMed] [Google Scholar]
  37. Ertekin-Taner N., Graff-Radford N., Younkin L. H., Eckman C., Baker M., Adamson J., Ronald J., Blangero J., Hutton M., Younkin S. G. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science. 2000 Dec 22;290(5500):2303–2304. doi: 10.1126/science.290.5500.2303. [DOI] [PubMed] [Google Scholar]
  38. Esler W. P., Kimberly W. T., Ostaszewski B. L., Diehl T. S., Moore C. L., Tsai J. Y., Rahmati T., Xia W., Selkoe D. J., Wolfe M. S. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol. 2000 Jul;2(7):428–434. doi: 10.1038/35017062. [DOI] [PubMed] [Google Scholar]
  39. Farzan M., Schnitzler C. E., Vasilieva N., Leung D., Choe H. BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9712–9717. doi: 10.1073/pnas.160115697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Feany M. B., Bender W. W. A Drosophila model of Parkinson's disease. Nature. 2000 Mar 23;404(6776):394–398. doi: 10.1038/35006074. [DOI] [PubMed] [Google Scholar]
  41. Grover A., Houlden H., Baker M., Adamson J., Lewis J., Prihar G., Pickering-Brown S., Duff K., Hutton M. 5' splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J Biol Chem. 1999 May 21;274(21):15134–15143. doi: 10.1074/jbc.274.21.15134. [DOI] [PubMed] [Google Scholar]
  42. Grundke-Iqbal I., Iqbal K., Tung Y. C., Quinlan M., Wisniewski H. M., Binder L. I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986 Jul;83(13):4913–4917. doi: 10.1073/pnas.83.13.4913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Gutekunst C. A., Li S. H., Yi H., Mulroy J. S., Kuemmerle S., Jones R., Rye D., Ferrante R. J., Hersch S. M., Li X. J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci. 1999 Apr 1;19(7):2522–2534. doi: 10.1523/JNEUROSCI.19-07-02522.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Guénette S. Y., Chen J., Ferland A., Haass C., Capell A., Tanzi R. E. hFE65L influences amyloid precursor protein maturation and secretion. J Neurochem. 1999 Sep;73(3):985–993. doi: 10.1046/j.1471-4159.1999.0730985.x. [DOI] [PubMed] [Google Scholar]
  45. Hackam A. S., Singaraja R., Wellington C. L., Metzler M., McCutcheon K., Zhang T., Kalchman M., Hayden M. R. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol. 1998 Jun 1;141(5):1097–1105. doi: 10.1083/jcb.141.5.1097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Hackam A. S., Singaraja R., Zhang T., Gan L., Hayden M. R. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. Hum Mol Genet. 1999 Jan;8(1):25–33. doi: 10.1093/hmg/8.1.25. [DOI] [PubMed] [Google Scholar]
  47. Harris D. A. Cellular biology of prion diseases. Clin Microbiol Rev. 1999 Jul;12(3):429–444. doi: 10.1128/cmr.12.3.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Hasegawa M., Crowther R. A., Jakes R., Goedert M. Alzheimer-like changes in microtubule-associated protein Tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation. J Biol Chem. 1997 Dec 26;272(52):33118–33124. doi: 10.1074/jbc.272.52.33118. [DOI] [PubMed] [Google Scholar]
  49. Hasegawa M., Smith M. J., Goedert M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett. 1998 Oct 23;437(3):207–210. doi: 10.1016/s0014-5793(98)01217-4. [DOI] [PubMed] [Google Scholar]
  50. Hazeki N., Tukamoto T., Goto J., Kanazawa I. Formic acid dissolves aggregates of an N-terminal huntingtin fragment containing an expanded polyglutamine tract: applying to quantification of protein components of the aggregates. Biochem Biophys Res Commun. 2000 Oct 22;277(2):386–393. doi: 10.1006/bbrc.2000.3682. [DOI] [PubMed] [Google Scholar]
  51. Heiser V., Scherzinger E., Boeddrich A., Nordhoff E., Lurz R., Schugardt N., Lehrach H., Wanker E. E. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6739–6744. doi: 10.1073/pnas.110138997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Heutink P. Untangling tau-related dementia. Hum Mol Genet. 2000 Apr 12;9(6):979–986. doi: 10.1093/hmg/9.6.979. [DOI] [PubMed] [Google Scholar]
  53. Hiesberger T., Trommsdorff M., Howell B. W., Goffinet A., Mumby M. C., Cooper J. A., Herz J. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron. 1999 Oct;24(2):481–489. doi: 10.1016/s0896-6273(00)80861-2. [DOI] [PubMed] [Google Scholar]
  54. Hodgson J. G., Agopyan N., Gutekunst C. A., Leavitt B. R., LePiane F., Singaraja R., Smith D. J., Bissada N., McCutcheon K., Nasir J. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999 May;23(1):181–192. doi: 10.1016/s0896-6273(00)80764-3. [DOI] [PubMed] [Google Scholar]
  55. Hong M., Zhukareva V., Vogelsberg-Ragaglia V., Wszolek Z., Reed L., Miller B. I., Geschwind D. H., Bird T. D., McKeel D., Goate A. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 1998 Dec 4;282(5395):1914–1917. doi: 10.1126/science.282.5395.1914. [DOI] [PubMed] [Google Scholar]
  56. Hsu L. J., Mallory M., Xia Y., Veinbergs I., Hashimoto M., Yoshimoto M., Thal L. J., Saitoh T., Masliah E. Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. J Neurochem. 1998 Jul;71(1):338–344. doi: 10.1046/j.1471-4159.1998.71010338.x. [DOI] [PubMed] [Google Scholar]
  57. Hussain I., Powell D., Howlett D. R., Tew D. G., Meek T. D., Chapman C., Gloger I. S., Murphy K. E., Southan C. D., Ryan D. M. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci. 1999 Dec;14(6):419–427. doi: 10.1006/mcne.1999.0811. [DOI] [PubMed] [Google Scholar]
  58. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 1994 Jul;13(1):45–53. doi: 10.1016/0896-6273(94)90458-8. [DOI] [PubMed] [Google Scholar]
  59. Jana N. R., Tanaka M., Wang G. h., Nukina N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum Mol Genet. 2000 Aug 12;9(13):2009–2018. doi: 10.1093/hmg/9.13.2009. [DOI] [PubMed] [Google Scholar]
  60. Janus C., Chishti M. A., Westaway D. Transgenic mouse models of Alzheimer's disease. Biochim Biophys Acta. 2000 Jul 26;1502(1):63–75. doi: 10.1016/s0925-4439(00)00033-8. [DOI] [PubMed] [Google Scholar]
  61. Janus C., Pearson J., McLaurin J., Mathews P. M., Jiang Y., Schmidt S. D., Chishti M. A., Horne P., Heslin D., French J. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000 Dec 21;408(6815):979–982. doi: 10.1038/35050110. [DOI] [PubMed] [Google Scholar]
  62. Jin H., Clayton D. F. Synelfin regulation during the critical period for song learning in normal and isolated juvenile zebra finches. Neurobiol Learn Mem. 1997 Nov;68(3):271–284. doi: 10.1006/nlme.1997.3795. [DOI] [PubMed] [Google Scholar]
  63. Kehoe P., Wavrant-De Vrieze F., Crook R., Wu W. S., Holmans P., Fenton I., Spurlock G., Norton N., Williams H., Williams N. A full genome scan for late onset Alzheimer's disease. Hum Mol Genet. 1999 Feb;8(2):237–245. doi: 10.1093/hmg/8.2.237. [DOI] [PubMed] [Google Scholar]
  64. Kosik K. S., Joachim C. L., Selkoe D. J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A. 1986 Jun;83(11):4044–4048. doi: 10.1073/pnas.83.11.4044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Lau K. F., McLoughlin D. M., Standen C., Miller C. C. X11 alpha and x11 beta interact with presenilin-1 via their PDZ domains. Mol Cell Neurosci. 2000 Nov;16(5):557–565. doi: 10.1006/mcne.2000.0898. [DOI] [PubMed] [Google Scholar]
  66. Lee V. M. Regulation of tau phosphorylation in Alzheimer's disease. Ann N Y Acad Sci. 1996 Jan 17;777:107–113. doi: 10.1111/j.1749-6632.1996.tb34408.x. [DOI] [PubMed] [Google Scholar]
  67. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000 Aug;25(4):402–405. doi: 10.1038/78078. [DOI] [PubMed] [Google Scholar]
  68. Li H., Li S. H., Cheng A. L., Mangiarini L., Bates G. P., Li X. J. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum Mol Genet. 1999 Jul;8(7):1227–1236. doi: 10.1093/hmg/8.7.1227. [DOI] [PubMed] [Google Scholar]
  69. Li Y. M., Lai M. T., Xu M., Huang Q., DiMuzio-Mower J., Sardana M. K., Shi X. P., Yin K. C., Shafer J. A., Gardell S. J. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6138–6143. doi: 10.1073/pnas.110126897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Li Y. M., Xu M., Lai M. T., Huang Q., Castro J. L., DiMuzio-Mower J., Harrison T., Lellis C., Nadin A., Neduvelil J. G. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 2000 Jun 8;405(6787):689–694. doi: 10.1038/35015085. [DOI] [PubMed] [Google Scholar]
  71. Lin X., Koelsch G., Wu S., Downs D., Dashti A., Tang J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1456–1460. doi: 10.1073/pnas.97.4.1456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Lovestone S., Hartley C. L., Pearce J., Anderton B. H. Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience. 1996 Aug;73(4):1145–1157. doi: 10.1016/0306-4522(96)00126-1. [DOI] [PubMed] [Google Scholar]
  73. Lovestone S., Reynolds C. H. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience. 1997 May;78(2):309–324. doi: 10.1016/s0306-4522(96)00577-5. [DOI] [PubMed] [Google Scholar]
  74. Lunkes A., Mandel J. L. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet. 1998 Sep;7(9):1355–1361. doi: 10.1093/hmg/7.9.1355. [DOI] [PubMed] [Google Scholar]
  75. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S. W. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996 Nov 1;87(3):493–506. doi: 10.1016/s0092-8674(00)81369-0. [DOI] [PubMed] [Google Scholar]
  76. Mann D. M., Esiri M. M. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci. 1989 Feb;89(2-3):169–179. doi: 10.1016/0022-510x(89)90019-1. [DOI] [PubMed] [Google Scholar]
  77. Martindale D., Hackam A., Wieczorek A., Ellerby L., Wellington C., McCutcheon K., Singaraja R., Kazemi-Esfarjani P., Devon R., Kim S. U. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet. 1998 Feb;18(2):150–154. doi: 10.1038/ng0298-150. [DOI] [PubMed] [Google Scholar]
  78. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000 Feb 18;287(5456):1265–1269. doi: 10.1126/science.287.5456.1265. [DOI] [PubMed] [Google Scholar]
  79. McLoughlin D. M., Irving N. G., Miller C. C. The Fe65 and X11 families of proteins: proteins that interact with the Alzheimer's disease amyloid precursor protein. Biochem Soc Trans. 1998 Aug;26(3):497–500. doi: 10.1042/bst0260497. [DOI] [PubMed] [Google Scholar]
  80. Mena R., Edwards P. C., Harrington C. R., Mukaetova-Ladinska E. B., Wischik C. M. Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Acta Neuropathol. 1996;91(6):633–641. doi: 10.1007/s004010050477. [DOI] [PubMed] [Google Scholar]
  81. Meyer M. R., Tschanz J. T., Norton M. C., Welsh-Bohmer K. A., Steffens D. C., Wyse B. W., Breitner J. C. APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease. Nat Genet. 1998 Aug;19(4):321–322. doi: 10.1038/1206. [DOI] [PubMed] [Google Scholar]
  82. Muchowski P. J., Schaffar G., Sittler A., Wanker E. E., Hayer-Hartl M. K., Hartl F. U. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7841–7846. doi: 10.1073/pnas.140202897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Murrell J. R., Spillantini M. G., Zolo P., Guazzelli M., Smith M. J., Hasegawa M., Redi F., Crowther R. A., Pietrini P., Ghetti B. Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits. J Neuropathol Exp Neurol. 1999 Dec;58(12):1207–1226. doi: 10.1097/00005072-199912000-00002. [DOI] [PubMed] [Google Scholar]
  84. Myers A., Holmans P., Marshall H., Kwon J., Meyer D., Ramic D., Shears S., Booth J., DeVrieze F. W., Crook R. Susceptibility locus for Alzheimer's disease on chromosome 10. Science. 2000 Dec 22;290(5500):2304–2305. doi: 10.1126/science.290.5500.2304. [DOI] [PubMed] [Google Scholar]
  85. Nacharaju P., Lewis J., Easson C., Yen S., Hackett J., Hutton M., Yen S. H. Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett. 1999 Mar 26;447(2-3):195–199. doi: 10.1016/s0014-5793(99)00294-x. [DOI] [PubMed] [Google Scholar]
  86. Narhi L., Wood S. J., Steavenson S., Jiang Y., Wu G. M., Anafi D., Kaufman S. A., Martin F., Sitney K., Denis P. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem. 1999 Apr 2;274(14):9843–9846. doi: 10.1074/jbc.274.14.9843. [DOI] [PubMed] [Google Scholar]
  87. Naruse S., Thinakaran G., Luo J. J., Kusiak J. W., Tomita T., Iwatsubo T., Qian X., Ginty D. D., Price D. L., Borchelt D. R. Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron. 1998 Nov;21(5):1213–1221. doi: 10.1016/s0896-6273(00)80637-6. [DOI] [PubMed] [Google Scholar]
  88. Perutz M. F. Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem Sci. 1999 Feb;24(2):58–63. doi: 10.1016/s0968-0004(98)01350-4. [DOI] [PubMed] [Google Scholar]
  89. Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997 Jun 27;276(5321):2045–2047. doi: 10.1126/science.276.5321.2045. [DOI] [PubMed] [Google Scholar]
  90. Price D. L., Sisodia S. S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci. 1998;21:479–505. doi: 10.1146/annurev.neuro.21.1.479. [DOI] [PubMed] [Google Scholar]
  91. Rizzini C., Goedert M., Hodges J. R., Smith M. J., Jakes R., Hills R., Xuereb J. H., Crowther R. A., Spillantini M. G. Tau gene mutation K257T causes a tauopathy similar to Pick's disease. J Neuropathol Exp Neurol. 2000 Nov;59(11):990–1001. doi: 10.1093/jnen/59.11.990. [DOI] [PubMed] [Google Scholar]
  92. Russo T., Faraonio R., Minopoli G., De Candia P., De Renzis S., Zambrano N. Fe65 and the protein network centered around the cytosolic domain of the Alzheimer's beta-amyloid precursor protein. FEBS Lett. 1998 Aug 28;434(1-2):1–7. doi: 10.1016/s0014-5793(98)00941-7. [DOI] [PubMed] [Google Scholar]
  93. Sabo S. L., Lanier L. M., Ikin A. F., Khorkova O., Sahasrabudhe S., Greengard P., Buxbaum J. D. Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein. J Biol Chem. 1999 Mar 19;274(12):7952–7957. doi: 10.1074/jbc.274.12.7952. [DOI] [PubMed] [Google Scholar]
  94. Sastre M., Turner R. S., Levy E. X11 interaction with beta-amyloid precursor protein modulates its cellular stabilization and reduces amyloid beta-protein secretion. J Biol Chem. 1998 Aug 28;273(35):22351–22357. doi: 10.1074/jbc.273.35.22351. [DOI] [PubMed] [Google Scholar]
  95. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999 Jul 8;400(6740):173–177. doi: 10.1038/22124. [DOI] [PubMed] [Google Scholar]
  96. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G. P., Davies S. W., Lehrach H., Wanker E. E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 1997 Aug 8;90(3):549–558. doi: 10.1016/s0092-8674(00)80514-0. [DOI] [PubMed] [Google Scholar]
  97. Schmechel D. E., Saunders A. M., Strittmatter W. J., Crain B. J., Hulette C. M., Joo S. H., Pericak-Vance M. A., Goldgaber D., Roses A. D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9649–9653. doi: 10.1073/pnas.90.20.9649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Selkoe D. J. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998 Nov;8(11):447–453. doi: 10.1016/s0962-8924(98)01363-4. [DOI] [PubMed] [Google Scholar]
  99. Selkoe D. J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 1999 Jun 24;399(6738 Suppl):A23–A31. doi: 10.1038/399a023. [DOI] [PubMed] [Google Scholar]
  100. Shen J., Bronson R. T., Chen D. F., Xia W., Selkoe D. J., Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 1997 May 16;89(4):629–639. doi: 10.1016/s0092-8674(00)80244-5. [DOI] [PubMed] [Google Scholar]
  101. Sinha S., Anderson J. P., Barbour R., Basi G. S., Caccavello R., Davis D., Doan M., Dovey H. F., Frigon N., Hong J. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999 Dec 2;402(6761):537–540. doi: 10.1038/990114. [DOI] [PubMed] [Google Scholar]
  102. Spillantini M. G., Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 1998 Oct;21(10):428–433. doi: 10.1016/s0166-2236(98)01337-x. [DOI] [PubMed] [Google Scholar]
  103. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997 Aug 28;388(6645):839–840. doi: 10.1038/42166. [DOI] [PubMed] [Google Scholar]
  104. Strittmatter W. J., Saunders A. M., Goedert M., Weisgraber K. H., Dong L. M., Jakes R., Huang D. Y., Pericak-Vance M., Schmechel D., Roses A. D. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11183–11186. doi: 10.1073/pnas.91.23.11183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Strittmatter W. J., Weisgraber K. H., Goedert M., Saunders A. M., Huang D., Corder E. H., Dong L. M., Jakes R., Alberts M. J., Gilbert J. R. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol. 1994 Feb;125(2):163–174. doi: 10.1006/exnr.1994.1019. [DOI] [PubMed] [Google Scholar]
  106. Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong L. M., Salvesen G. S., Pericak-Vance M., Schmechel D., Saunders A. M., Goldgaber D., Roses A. D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8098–8102. doi: 10.1073/pnas.90.17.8098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Teller J. K., Russo C., DeBusk L. M., Angelini G., Zaccheo D., Dagna-Bricarelli F., Scartezzini P., Bertolini S., Mann D. M., Tabaton M. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med. 1996 Jan;2(1):93–95. doi: 10.1038/nm0196-93. [DOI] [PubMed] [Google Scholar]
  108. Telling G. C. Prion protein genes and prion diseases: studies in transgenic mice. Neuropathol Appl Neurobiol. 2000 Jun;26(3):209–220. doi: 10.1046/j.1365-2990.2000.00253.x. [DOI] [PubMed] [Google Scholar]
  109. Tomita S., Ozaki T., Taru H., Oguchi S., Takeda S., Yagi Y., Sakiyama S., Kirino Y., Suzuki T. Interaction of a neuron-specific protein containing PDZ domains with Alzheimer's amyloid precursor protein. J Biol Chem. 1999 Jan 22;274(4):2243–2254. doi: 10.1074/jbc.274.4.2243. [DOI] [PubMed] [Google Scholar]
  110. Trommsdorff M., Borg J. P., Margolis B., Herz J. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem. 1998 Dec 11;273(50):33556–33560. doi: 10.1074/jbc.273.50.33556. [DOI] [PubMed] [Google Scholar]
  111. Ulery P. G., Beers J., Mikhailenko I., Tanzi R. E., Rebeck G. W., Hyman B. T., Strickland D. K. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem. 2000 Mar 10;275(10):7410–7415. doi: 10.1074/jbc.275.10.7410. [DOI] [PubMed] [Google Scholar]
  112. Vassar R., Bennett B. D., Babu-Khan S., Kahn S., Mendiaz E. A., Denis P., Teplow D. B., Ross S., Amarante P., Loeloff R. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999 Oct 22;286(5440):735–741. doi: 10.1126/science.286.5440.735. [DOI] [PubMed] [Google Scholar]
  113. Vekrellis K., Ye Z., Qiu W. Q., Walsh D., Hartley D., Chesneau V., Rosner M. R., Selkoe D. J. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci. 2000 Mar 1;20(5):1657–1665. doi: 10.1523/JNEUROSCI.20-05-01657.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Vickers J. C., Dickson T. C., Adlard P. A., Saunders H. L., King C. E., McCormack G. The cause of neuronal degeneration in Alzheimer's disease. Prog Neurobiol. 2000 Feb;60(2):139–165. doi: 10.1016/s0301-0082(99)00023-4. [DOI] [PubMed] [Google Scholar]
  115. Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto M., Takahashi H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett. 1997 Dec 12;239(1):45–48. doi: 10.1016/s0304-3940(97)00891-4. [DOI] [PubMed] [Google Scholar]
  116. Wellington C. L., Singaraja R., Ellerby L., Savill J., Roy S., Leavitt B., Cattaneo E., Hackam A., Sharp A., Thornberry N. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem. 2000 Jun 30;275(26):19831–19838. doi: 10.1074/jbc.M001475200. [DOI] [PubMed] [Google Scholar]
  117. Whittington M. A., Sidle K. C., Gowland I., Meads J., Hill A. F., Palmer M. S., Jefferys J. G., Collinge J. Rescue of neurophysiological phenotype seen in PrP null mice by transgene encoding human prion protein. Nat Genet. 1995 Feb;9(2):197–201. doi: 10.1038/ng0295-197. [DOI] [PubMed] [Google Scholar]
  118. Withers G. S., George J. M., Banker G. A., Clayton D. F. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res. 1997 Mar 17;99(1):87–94. doi: 10.1016/s0165-3806(96)00210-6. [DOI] [PubMed] [Google Scholar]
  119. Wolfe M. S., Xia W., Ostaszewski B. L., Diehl T. S., Kimberly W. T., Selkoe D. J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999 Apr 8;398(6727):513–517. doi: 10.1038/19077. [DOI] [PubMed] [Google Scholar]
  120. Wong P. C., Zheng H., Chen H., Becher M. W., Sirinathsinghji D. J., Trumbauer M. E., Chen H. Y., Price D. L., Van der Ploeg L. H., Sisodia S. S. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature. 1997 May 15;387(6630):288–292. doi: 10.1038/387288a0. [DOI] [PubMed] [Google Scholar]
  121. Wood S. J., Wypych J., Steavenson S., Louis J. C., Citron M., Biere A. L. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem. 1999 Jul 9;274(28):19509–19512. doi: 10.1074/jbc.274.28.19509. [DOI] [PubMed] [Google Scholar]
  122. Wyttenbach A., Carmichael J., Swartz J., Furlong R. A., Narain Y., Rankin J., Rubinsztein D. C. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2898–2903. doi: 10.1073/pnas.97.6.2898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Yan R., Bienkowski M. J., Shuck M. E., Miao H., Tory M. C., Pauley A. M., Brashier J. R., Stratman N. C., Mathews W. R., Buhl A. E. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature. 1999 Dec 2;402(6761):533–537. doi: 10.1038/990107. [DOI] [PubMed] [Google Scholar]
  124. Zhang Z., Nadeau P., Song W., Donoviel D., Yuan M., Bernstein A., Yankner B. A. Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1. Nat Cell Biol. 2000 Jul;2(7):463–465. doi: 10.1038/35017108. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES